天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01779 天辰生物-B

已收盘 08-20 16:09:07

116.400

+11.200

+10.65%

最高119.300	最低104.100	成交量6.36万
今开106.100	昨收105.200	日振幅14.45%
总市值88.84亿	流通市值87.37亿	总股本7,632万
成交额728.58万	换手率0.08%	流通股本7,506万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"天辰生物-B","latestPrice":116.4,"timestamp":1787213347666,"preClose":105.2,"halted":0,"volume":63600,"delay":0,"changeRate":0.10646387832699622,"floatShares":75059200,"shares":76322100,"eps":-3.616829610181191,"marketStatus":"已收盘","change":11.2,"latestTime":"08-20 16:09:07","open":106.1,"high":119.3,"low":104.1,"amount":7285802,"amplitude":0.144487,"askPrice":116.4,"askSize":150,"bidPrice":114.5,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-2.9717930112165662,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":105.2,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":0.736057,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01779","defaultTab":"news","newsList":[{"id":"2658991610","title":"天辰生物－Ｂ(01779.HK)拟8月21日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2658991610","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658991610?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:17","pubTimestamp":1786443422,"startTime":"0","endTime":"0","summary":"格隆汇8月11日丨天辰生物－Ｂ(01779.HK)宣布，董事会会议将于2026年8月21日(星期五)举行，藉以(其中包括)审议及批准公司及其附属公司截至2026年6月30日止六个月的未经审核中期业绩及其发布，并考虑派发中期股息(如有)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260811/32331846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161151651","title":"天辰生物-B（01779）拟于2026年8月21日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1161151651","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161151651?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:01","pubTimestamp":1786442486,"startTime":"0","endTime":"0","summary":"天辰生物-B（01779）8月11日在港交所公告称，公司董事会已定于2026年8月21日（星期五）召开会议，主要议程包括：审议及批准本公司及其附属公司截至2026年6月30日止六个月之未经审核中期业绩并予以发布，并考虑是否派发中期股息（如有）。\\n\\n公告显示，董事会成员包括执行董事刘恒博士、孙乃超博士及谢鸣先生；非执行董事藺剑先生、顾勤女士、薛滌博士及陈侃博士；以及独立非执行董事萧耀熙先生、阮添士先生、杨春先生和周国防先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103585266","title":"天辰生物-B发布2026年7月股份变动月报，股本增至76,322,100股","url":"https://stock-news.laohu8.com/highlight/detail?id=1103585266","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103585266?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:05","pubTimestamp":1786014345,"startTime":"0","endTime":"0","summary":"天辰生物-B于2026年8月6日发布了截至2026年7月31日的股份变动月报表。公告显示，公司注册于中华人民共和国，法定/注册股本在2026年7月期间发生以下变化：。公司于本月末的法定/注册股本总额为人民币76,322,100元。其中，H股法定/注册股本自6月底的72,930,268股增加2,128,950股，至7月底的75,059,218股；未上市股份1,262,882股维持不变。公司于2026年7月6日因悉数行使超额配股权，以每股港币96.06元的价格发行并配发2,128,950股H股。公告由执行董事谢鸣代表公司签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651491999","title":"天辰生物-B(01779)：建议采纳H股购股权计划及H股股份激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2651491999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651491999?lang=zh_cn&edition=full","pubTime":"2026-07-16 06:49","pubTimestamp":1784155756,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，于2026年7月15日，董事会已决议建议采纳本公司的H股购股权计划及H股股份激励计划。就根据H股购股权计划及H股股份激励计划将予授出的所有购股权及股份奖励，以及根据本公司任何其他股份计划将予授出的所有购股权及股份奖励而可予配发及发行或自库存转出的H股最高数目，不得超过于本公司股东批准该计划限额当日本公司已发行股份总数的10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1151962904","title":"天辰生物-B（01779）拟设立H股购股权及股份激励计划　总额度上限为已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151962904","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151962904?lang=zh_cn&edition=full","pubTime":"2026-07-16 06:10","pubTimestamp":1784153455,"startTime":"0","endTime":"0","summary":"天辰生物-B（01779）7月16日公告称，公司董事会已于2026年7月15日审议通过，拟在股东特别大会上提请批准设立H股购股权计划及H股股份激励计划（合称“股份计划”）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651846430","title":"港股异动 | 天辰生物-B(01779.HK)涨超7% 近日LP-003针对花生过敏适应症的临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651846430","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651846430?lang=zh_cn&edition=full","pubTime":"2026-07-15 15:12","pubTimestamp":1784099575,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651161474","title":"天辰生物-B(01779)：LP-003针对花生过敏适应症的临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651161474","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651161474?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:16","pubTimestamp":1783901809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对花生过敏适应症的临床试验申请已获美国食品药品监督管理局批准。LP-003是一种具有新型序列设计的抗IgE抗体。LP-003的主要功能是阻断血液和组织中的游离IgE，从而抑制IgE介导的过敏反应的发生。LP-003能够结合游离IgE，阻止该等游离且过量的IgE与高亲和力IgE受体FcεRI结合。公司已在中国获得LP-003针对多种适应症的IND批准及╱或启动相关临床试验，包括季节性过敏性鼻炎、CSU、过敏性哮喘、CRSwNP及食物过敏。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LABU","01779","IBBQ","BK4585","BK4588","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651161440","title":"天辰生物-B(01779.HK)存仓市值总计9.27亿港元 公司股东将1033.78万股股票存入国金证券香港","url":"https://stock-news.laohu8.com/highlight/detail?id=2651161440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651161440?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:11","pubTimestamp":1783901508,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104968653","title":"天辰生物-B（01779）LP-003治疗花生过敏IND获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1104968653","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104968653?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:11","pubTimestamp":1783901501,"startTime":"0","endTime":"0","summary":"2026年7月13日，天辰生物医药（苏州）股份有限公司发布自愿公告称，其自主研发的抗IgE抗体LP-003针对花生过敏的临床试验申请已获美国食品药品监督管理局批准。\\n\\n公告显示，LP-003是一款具有新型序列设计的抗IgE抗体，主要通过阻断血液和组织中的游离IgE，抑制IgE介导的过敏反应。\\n\\n公司在公告中提示，尚无法保证LP-003能够最终成功上市，提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149362957","title":"天辰生物-B因悉数行使超额配股权配发2,128,950股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1149362957","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149362957?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:24","pubTimestamp":1783337045,"startTime":"0","endTime":"0","summary":"天辰生物-B（01779）于2026年7月6日发布公告，披露公司因悉数行使超额配股权增发H股，涉及的发行及配发股份总数为2,128,950股，变动日期为2026年7月6日。\n根据公告，此次增发的2,128,950股约占本次发行前公司已发行股本的2.92%，每股发行价格为96.06港元。增发完成后，公司已发行股本由72,930,268股增至75,059,218股，库藏股数仍为0股。\n公司于公告中确认已遵守相关上市规则及法律法规。本次披露文件由执行董事谢鸣签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"天辰生物-B因悉数行使超额配股权配发2,128,950股H股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649626332","title":"天辰生物-B(01779)因悉数行使超额配股权而发行212.895万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649626332","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649626332?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:18","pubTimestamp":1783336719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B(01779)发布公告，于2026年7月6日因悉数行使超额配股权而发行及配发212.895万H股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125387826","title":"天辰生物-B更新2026年6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125387826","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125387826?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:05","pubTimestamp":1783335959,"startTime":"0","endTime":"0","summary":"天辰生物醫藥(蘇州)股份有限公司于2026年7月6日发布截至2026年6月30日止月份的股份变动月报表。公告显示，公司注册于中华人民共和国，其H股已于2026年6月5日正式在香港联合交易所有限公司主板上市。根据月报表，天辰生物-B于报告期内法定/注册股本总额为人民币74,193,150元，包含72,930,268股H股及1,262,882股未上市股份，均为每股面值人民币1元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648323501","title":"天辰生物-B(01779)：稳定价格行动及稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2648323501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648323501?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:42","pubTimestamp":1782988960,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，本公司宣布，有关全球发售的稳定价格期已于2026年7月2日(星期四)结束。于稳定价格期，稳定价格操作人并无为稳定价格而在市场上购买或出售任何H股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648324573","title":"天辰生物-B创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2648324573","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648324573?lang=zh_cn&edition=full","pubTime":"2026-07-02 09:56","pubTimestamp":1782957411,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06872","01651","09637","01672","01779","02616","02632","07688","01440","01956","06658","03388","02142","01866","02723","00412","01236","06636","03661","03277","07630","02553","02696","02272","00100","02526","03310","01021","07666","01286","BK4585","06938","03355","06106","00068","02670","01191","09630","BK4588","02672","03625","00340","01133","01511","06656","02729","01081","01609","00376","03887","02726","01392","00600","00863","01879","06675","02335"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647755290","title":"天辰生物-B(01779)：超额配股权获悉数行使","url":"https://stock-news.laohu8.com/highlight/detail?id=2647755290","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647755290?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:29","pubTimestamp":1782829773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B(01779)公布，独家保荐人兼整体协调人(为其本身及代表国际包销商)已于2026年 6月30日(星期二)悉数行使招股章程所述的超额配股权，涉及合共212.895万股H 股，占于任何超额配股权获行使前全球发售项下初步可供认购发售股份总数的约 15%。因超额配股权获行使而将予发行的H股将由公司按每股H股 96.06港元配发及发行。超额配发股份将用于促成将部分H股交付予已同意延迟交付其根据全球发售认购的相关H股的承配人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647958949","title":"港股异动 | 天辰生物-B(01779.HK)涨超6% LP-003针对季节性过敏性鼻炎适应症III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2647958949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647958949?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:02","pubTimestamp":1782788555,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647589491","title":"港股异动 | 天辰生物-B(01779)涨超6% LP-003针对季节性过敏性鼻炎适应症III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2647589491","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647589491?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:02","pubTimestamp":1782788555,"startTime":"0","endTime":"0","summary":"消息面上，近日，天辰生物-B发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。此外，LP-003 II期临床数据初步展现出超越奥马珠单抗的潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01779","BK4134","BK1161","VXUS","III","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237531","title":"天辰生物-B(01779)：LP-003针对季节性过敏性鼻炎适应症的III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237531","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642237531?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:16","pubTimestamp":1781216203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天辰生物-B 发布公告，LP-003针对季节性过敏性鼻炎的III期临床试验已达到预先设定的主要终点，且该等结果在统计学及临床方面均具有高度重要性。LP-003针对季节性过敏性鼻炎适应症的III期临床试验是一项在中国开展的多中心、随机、双盲、安慰剂对照的III期临床研究，旨在比较LP-003与安慰剂治疗经标准治疗控制不佳的中重度季节性过敏性鼻炎的效果。主要排除标准为患有季节性过敏性鼻炎以外的合并症的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4134","01779"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1123467918","title":"天辰生物-B：LP-3治疗季节性过敏性鼻炎III期临床试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123467918","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123467918?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:13","pubTimestamp":1781215995,"startTime":"0","endTime":"0","summary":"天辰生物-B宣布，其用于治疗季节性过敏性鼻炎的候选药物LP-3，在关键的III期临床试验中成功达到了预设的主要疗效终点。这一积极结果标志着该药物在临床开发道路上取得了重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longbio.com","stockEarnings":[{"period":"1week","weight":-0.1717},{"period":"1month","weight":0.1541},{"period":"3month","weight":0.0951},{"period":"ytd","weight":0.0951}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"天辰生物医药（苏州）股份有限公司是一家主要从事过敏性及自身免疫性疾病的生物药物自主发现与开发的中国公司。该公司的研发平台主要包括高亲和力抗体发现平台和双功能抗体开发平台。该公司的药物治疗方向主要包括季节性过敏性鼻炎（AR）、慢性自发性荨麻疹（CSU）、过敏性哮喘、食物过敏以及其他过敏性疾病、阵发性睡眠性血红蛋白尿症（PNH）、补体介导肾脏疾病、C3肾小球病（C3G）和狼疮性肾炎（LN）及其他补体相关适应症。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"天辰生物-B","nameEN":"LONGBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天辰生物-B,01779,天辰生物-B股票,天辰生物-B股票老虎,天辰生物-B股票老虎国际,天辰生物-B行情,天辰生物-B股票行情,天辰生物-B股价,天辰生物-B股市,天辰生物-B股票价格,天辰生物-B股票交易,天辰生物-B股票购买,天辰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天辰生物-B(01779)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天辰生物-B(01779)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}